Alan Pollack
YOU?
Author Swipe
View article: Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence
Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence Open
Purpose: Clinical risk grouping based on PSA, tumor grade, and disease extent guides treatment intensity for localized prostate cancer. However, many patients with intermediate- or high-risk disease treated with external beam radiotherapy …
View article: Prostate-specific EV capture with sufficient RNA yield to enable transcriptomic profiling
Prostate-specific EV capture with sufficient RNA yield to enable transcriptomic profiling Open
Prostate-specific antigen (PSA) screening has reduced prostate cancer (PCa) mortality but suffers from limited specificity, contributing to unnecessary biopsies and overdiagnosis of indolent disease. There is a critical need for biofluid-b…
View article: Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data Open
Short- or long-course HT after postoperative RT improves MFS and PCSS. Observed improvements in OS are small and may be limited to people with higher-risk factors.
View article: Accelerated X-Ray Fluorescence Computed Tomography via Multi-Pencil-Beam Excitation
Accelerated X-Ray Fluorescence Computed Tomography via Multi-Pencil-Beam Excitation Open
X-ray fluorescence computed tomography (XFCT), a form of X-ray molecular imaging, offers detailed quantitative imaging capabilities for high-Z metal nanoparticles (MNPs), which are widely studied for their applications in multifunctional t…
View article: Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials Open
In the SAKK 09/10 and RTOG 0126 randomized controlled trials, we demonstrated that PORTOS can potentially identify a subset of patients who benefit from DE, a subgroup that cannot be identified using clinicopathological or prognostic varia…
View article: A Smart Water Bottle and Companion App (HidrateSpark 3) to Improve Bladder-Filling Compliance in Patients With Prostate Cancer Receiving Radiotherapy: Nonrandomized Trial of Feasibility and Acceptability
A Smart Water Bottle and Companion App (HidrateSpark 3) to Improve Bladder-Filling Compliance in Patients With Prostate Cancer Receiving Radiotherapy: Nonrandomized Trial of Feasibility and Acceptability Open
Background Patients with prostate cancer undergoing radiation therapy (RT) need comfortably full bladders to reduce toxicities during treatment. Poor compliance is common with standard of care written or verbal instructions, leading to was…
View article: Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers
Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers Open
Objectives There are 2 grading approaches to radical prostatectomy (RP) in multifocal cancer: Grade Group (GG) and percentage of Gleason pattern 4 (GP4%). We investigated whether RP GG and GP4% generated by global vs individual tumor gradi…
View article: Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer
Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer Open
: Prostate cancer (PCa) is the most frequent and second-lethal cancer among men. Despite considerable efforts to explore treatments like autologous cellular immunotherapy and immune checkpoint inhibitors, their success remains limited. The…
View article: Uncovering prostate cancer aggressiveness signal in T2‐weighted MRI through a three‐reference tissues normalization technique
Uncovering prostate cancer aggressiveness signal in T2‐weighted MRI through a three‐reference tissues normalization technique Open
Quantitative T2‐weighted MRI (T2W) interpretation is impeded by the variability of acquisition‐related features, such as field strength, coil type, signal amplification, and pulse sequence parameters. The main purpose of this work is to de…
View article: Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI
Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI Open
The utilization of multi-parametric MRI (mpMRI) in clinical decisions regarding prostate cancer patients’ management has recently increased. After biopsy, clinicians can assess risk using National Comprehensive Cancer Network (NCCN) risk s…
View article: A Smart Water Bottle and Companion App (HidrateSpark 3) to Improve Bladder-Filling Compliance in Patients With Prostate Cancer Receiving Radiotherapy: Nonrandomized Trial of Feasibility and Acceptability (Preprint)
A Smart Water Bottle and Companion App (HidrateSpark 3) to Improve Bladder-Filling Compliance in Patients With Prostate Cancer Receiving Radiotherapy: Nonrandomized Trial of Feasibility and Acceptability (Preprint) Open
BACKGROUND Patients with prostate cancer undergoing radiation therapy (RT) need comfortably full bladders to reduce toxicities during treatment. Poor compliance is common with standard of care written or verbal instructions, leading to wa…
View article: Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody–Gaussia Luciferase Fusion Protein
Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody–Gaussia Luciferase Fusion Protein Open
In vivo imaging has enabled impressive advances in biological research, both preclinical and clinical, and researchers have an arsenal of imaging methods available. Bioluminescence imaging is an advantageous method for in vivo studies that…
View article: Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence
Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence Open
STRUCTURED ABSTRACT Background Patients with localized prostate cancer have historically been assigned to clinical risk groups based on local disease extent, serum prostate specific antigen (PSA), and tumor grade. Clinical risk grouping is…
View article: Classifying Malignancy in Prostate Glandular Structures from Biopsy Scans with Deep Learning
Classifying Malignancy in Prostate Glandular Structures from Biopsy Scans with Deep Learning Open
Histopathological classification in prostate cancer remains a challenge with high dependence on the expert practitioner. We develop a deep learning (DL) model to identify the most prominent Gleason pattern in a highly curated data cohort a…
View article: Supplementary Figure S2: ATF3 knockdown via siATF3 inhibits apoptosis in VCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Supplementary Figure S2: ATF3 knockdown via siATF3 inhibits apoptosis in VCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity Open
Cells were harvested after 24 hours following treatment and caspase 3/7 assay was carried out. For ATF3 knockdown, VCaP were transfected with control siRNA or siATF3 (10 nM), followed by treatment with edelfosine (5 µM). Data shown represe…
View article: Supplementary Figure Legends from Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses
Supplementary Figure Legends from Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses Open
S1. VSV-hIFNβ treatment followed by RT caused S-phase cell cycle arrest of prostate cancer cells. S2. VSV treatment in combination with radiation therapy increases the GFP or Luciferase expression in vitro and in vivo. S3. C57BL/6 CD8 Re-c…
View article: Supplementary Figure S1: Edelfosine and ADT inhibits cell proliferation in VCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Supplementary Figure S1: Edelfosine and ADT inhibits cell proliferation in VCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity Open
VCaP cells were grown for 24 h in complete (A) or AD (B) medium. Cells were treated with edelfosine (1, 2.5, 5, 10 and 20 µM) with control groups receiving PBS (0.01 M) vehicle (S1A) VCaP and (S1B) VCaP + AD. Cells were monitored and cell …
View article: Data from Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses
Data from Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses Open
Vesicular stomatitis virus (VSV) expressing IFNβ induces apoptosis in multiple tumor models while maintaining an excellent safety profile. VSV-IFNβ is oncoselective due to permissive replication in cells with an altered IFN pathway. The hu…
View article: Supplementary Figures from Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses
Supplementary Figures from Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses Open
Supplementary Figures 1-3
View article: Supplementary Figure S5: Elevated ATF3 after AD and edelfosine treatments inhibits AR promoter activity in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Supplementary Figure S5: Elevated ATF3 after AD and edelfosine treatments inhibits AR promoter activity in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity Open
Androgen deprived LNCaP cells were co-transfected with 5 µg of ARE-luciferase reporter constructs, renilla luciferase and siATF3 (10 nM), followed by treatment with edelfosine (5 µM) and R1881 (5 nM). Cells were harvested and lysed after 2…
View article: Supplementary Figure S2: ATF3 knockdown via siATF3 inhibits apoptosis in VCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Supplementary Figure S2: ATF3 knockdown via siATF3 inhibits apoptosis in VCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity Open
Cells were harvested after 24 hours following treatment and caspase 3/7 assay was carried out. For ATF3 knockdown, VCaP were transfected with control siRNA or siATF3 (10 nM), followed by treatment with edelfosine (5 µM). Data shown represe…
View article: Supplementary Figure Legends from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Supplementary Figure Legends from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity Open
Supplementary Figure legends for Figures S1-S5.
View article: Supplementary Figure S4: ATF3 represses AR transcriptional target PSA expression in LNCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Supplementary Figure S4: ATF3 represses AR transcriptional target PSA expression in LNCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity Open
Parallel experiments were done with the treatment groups as in Figure 4A to study the effect of role of edelfosine and AD mediated AR transcriptional activity. Briefly, androgen deprived LNCaP cells were co-transfected with of PSA reporter…